Omnipod® 5 for Kids and Teens​

Omnipod 5 Pod right no adhesive Omnipod 5 Pod right no adhesive
Pod shown without necessary adhesive.​

The best of both worlds

Omnipod 5 is the only tubeless automated insulin delivery device in the US cleared for ages 2+.

The System integrates with a compatible glucose sensor to automatically increase, decrease, or pause insulin delivery to help protect against highs and lows, day and night.1.2

Long gone are the days of choosing between automated insulin delivery and tubeless freedom. Now kids, teens, and their caregivers can have the best of both worlds, all in one.




 

Peace of mind for parents

Omnipod 5 is the System that’s always adjusting, so you don’t have to be. SmartAdjust™ technology predicts glucose levels 60 minutes into the future and makes automatic insulin delivery adjustments to help manage glucose levels. ​

  

Icon Stop Clock svg

More time in range

Clinical study participants showed improved time in range by 3.7 hours per day in children (2.6 hours per day in children ages 2-5.9 years) and 2.2 hours per day in adolescents and adults.1,2​

Icon Lower A1C svg

Lower A1C​

Clinical study participants experienced a reduction in A1C of 0.71% in children (0.5% in children ages 2-5.9 years) and 0.38% in adolescents and adults.1,2​

Icon Stop Clock svg

Helps protect against lows​

Clinical study participants reduced time in hypoglycemia by 4 minutes per day in children ages 2-5.9 and 13 minutes per day in adolescents and adults, while lows remained minimal in children ages 6-14.1,2​

In a 3-month clinical study, 3 cases of severe hypoglycemia and 1 case of diabetic ketoacidosis (DKA) were reported in children and adults/adolescents during Omnipod 5 System use. These cases were not related to automated insulin delivery malfunction.​

Podder Gracie sitting on stairs Podder Gracie sitting on stairs

“Life with diabetes is not easy, but since
Omnipod 5, life is easier.”

--Hannah B., mom to Podder Gracie ​

Tubeless freedom for kids

Omnipod 5 is the only tubeless automated insulin delivery system in the US, which means your child can focus less on type 1 diabetes and more on the important things – like just being a kid. ​

  

No multiple daily injections—Omnipod delivers insulin continuously for 3 days (up to 72 hours)

Waterproof—can be worn while swimming, bathing, or showering – no need to ever disconnect

Tangle-proof—no tubes to get caught when playing with friends or going to soccer practice

Discreet—small enough to be worn under clothing with the Omnipod 5 App that makes insulin delivery look like sending a text​

Simple mealtimes – an integrated bolus calculator that eliminates complicated math at meal and snack times ​

Durable—ideal for competitive sports and active lifestyles​

Omnipod Pod placement guide Omnipod Pod placement guide

Wear the Pod with ease

The Pod can be worn anywhere you’d give an injection, which means there are plenty of options to suit your child’s preferences. ​

Plus, unlike traditional insulin pumps, there’s no need to disconnect for activities like showering, swimming, or sports, which means no interruption in automated insulin delivery. ​

Check your coverage

Choose your preferred path to answer a few questions. Once complete, a member of the Omnipod Pharmacy support team** will reach out with your expected copay and free trial†† eligibility.​

Icon Check Benefits

I’d like to check my coverage

Find out your estimated copay
Icon Free Trial

I'd like a free trial of Omnipod††

Take the Pod for a test drive

Experience award-winning automation​

Omnipod 5 boasts outstanding design and engineering, recognized by the CES Innovation Awards in 2022.​ ​

Using SmartAdjust™ technology, the Pod and a compatible CGM are in constant communication, enabling automatic insulin adjustments to help keep you in range.1,2​

CGM Pod Cycle CGM Pod Cycle
Omnipod 5 Aid Infographic No Disclaimer 1800x950 Omnipod 5 Aid Infographic No Disclaimer 1800x950

Ready to get started?

Risk Statement   

The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoRapid®, Humalog®, and Admelog®.The Omnipod 5 Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.   

WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.   

WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

1. Study in 80 people with T1D aged 2 -5.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (6AM-12AM) from CGM in standard therapy vs Omnipod 5 = 58.2% vs. 64.3%. Average time in Target Glucose range (12AM-6AM) from CGM in standard therapy vs. Omnipod 5 = 60.6% vs 82.4%. Average overnight time (12AM-6AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.1% vs. 20.7%; 42.2% vs. 20.7%. Average day time (6AM-12AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.6% vs. 26.1%; 46.4% vs. 33.4%. Median overnight time (12AM-6AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 2.07% vs. 0.82%; 0.78% vs. 0.78%. Median day time (6AM-12AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 1.91% vs. 1.08%; 1.17% vs. 1.62%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. SherrJL, et al. Diabetes Care (2022).  
2. Study in 240 people with T1D aged 6 -70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%. Average day time (6AM-12AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM-6AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Average time with high blood glucose overnight from CGM in standard therapy vs. Omnipod 5 = 38.4% vs. 16.9%. Average time with high blood during daytime from CGM in standard therapy vs. Omnipod 5 = 39.7% vs. 33.7%. Average time with low blood glucose overnight from CGM in standard therapy vs. Omnipod 5 = 3.41% vs. 2.13%. Average time with low blood glucose during daytime from CGM in standard therapy vs. Omnipod 5 = 3.44% vs. 2.57%. Average A1c in adults/adolescents and children, standard therapy vs. Omnipod 5 = 7.16% vs 6.78%; 7.67% vs 6.99%. Brown et al. Diabetes Care (2021).

*The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof. 
**ASPN Pharmacies and its dedicated staff power the Omnipod Pharmacy Support Program. The ASPN team is here for you to check your coverage and help coordinate fulfillment at your pharmacy of choice.

††Omnipod® 5 10-Day Free Trial 
Terms and Conditions

1. Program Eligibility

Eligibility criteria: Subject to program limitations and terms and conditions, the Omnipod 5 10-day Free Trial Program (the “Program”) is open to patients who have a valid Omnipod 5 and Dexcom G6 or Dexcom G7 prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. In order to be eligible, the patient’s eligible insurance plan must include coverage for Omnipod 5 Pods. The Program is open to new Pod Therapy patients coming from multiple daily injections or tubed pumps only who have not previously used Omnipod 5, Omnipod DASH®️ or Omnipod Insulin Management System.

This offer is not valid for participants whose Omnipod 5, Dexcom G6 or Dexcom G7 prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying participants or where prohibited by law. A participant is considered cash-paying where the participant has no insurance coverage for Omnipod 5 or where the participant has commercial or private insurance but Insulet determines in its sole discretion the participant is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Omnipod 5 prescription. Participants on certain commercial insurance plans may not be eligible. This offer is only valid in the United States, Puerto Rico, and the U.S. territories. Participants receiving their products through the Durable Medical Equipment or Pharmacy Durable Medical Equipment channel are not eligible to participate in the copay card program. Please contact Insulet Customer Support at 1-800-591-3455 for details.

2. Program Details

With this program, Participants may be eligible to receive a limited supply of Omnipod 5 products at no cost for them. Eligible participants have two (2) options, based on the following:

• A participant shall sign the Try Omnipod 5 Free Trial Acknowledgement through the appropriate platform provided by Insulet.

• Once Insulet has received the request, the request shall be escalated to Insulet’s pharmacy partner, where a request for a prescription shall be sent to the participant’s healthcare professional. If a valid prescription is received, both for the Omnipod 5 Intro Kit and the Omnipod 5 Pods, the participant’s benefits will be checked by Insulet or its partners.

  a. IF the benefits check results in a monthly copay equal to or below two hundred dollars ($200), then Insulet shall issue a one-time only copay card to the participant, for a value equal to the out-of-pocket expenses the participant would have to pay for an Omnipod 5 Intro Kit, in accordance with Section 3, below.

  b. IF the benefits check result in a copay greater than two hundred dollars ($200), Insulet, or its authorized partners, shall arrange for the shipment of one (1) Omnipod 5 Intro Kit, in accordance with Section 4, below.

  c. For the purpose of clarity, the term “copay” shall encompass any out-of-pocket expense for one (1) month’s supply of Pods, including any deductible, copays and other out-of-pocket expenses that the participant would have to disburse to procure said supply of Pods.

  d. Any copay assistance may not apply to a participant’s health plan’s deductible if prohibited by state law or by a health plan.

  e. In order to use the Omnipod 5 System in Automated Mode, the User must also procure a Dexcom G6 or Dexcom G7 Continuous Glucose Monitor System. For more information about how to obtain a 10-day supply of Dexcom G6 or Dexcom G7, please contact Dexcom or click on the following link: http://www.dexcom.com/SampleOP5.
Insulet reserves the right to change, amend or rescind this Program, in whole or in part, at any time.

3. Copay Card

 Should participant be deemed eligible to receive an Omnipod 5 Copay Card, participant shall receive electronically one (1) Omnipod 5 Copay Card, valid for a single use, in the amount required for the participant to procure one (1) Omnipod 5 Intro Kit, which shall include:

- One (1) Omnipod 5 Controller

- Ten (10) Omnipod 5 Pods

- One (1) Omnipod 5 User Guide

- One (1) Controller charging cable

4. Product Dispense

 Should participant be deemed eligible to receive a one-time dispense of Omnipod 5 Pods at no cost to them, Insulet, or its authorized partner, shall dispense one (1) Omnipod 5 Intro Kit, which shall include:

- One (1) Omnipod 5 Controller

- Ten (10) Omnipod 5 Pods

- One (1) Omnipod 5 User Guide

- One (1) Controller charging cable

The Omnipod 5 Intro Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Intro Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Intro Kit and to verify the content of the Intro Kit.